Evidence map›Paper›PMID 29286561›Full record

ArticlePediatric blood & cancer2018

Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

William J Hammond, Gadi Lalazar, James A Saltsman, Benjamin A Farber, Enrico Danzer, Tshering C Sherpa, Charles D Banda, Jeffrey R Andolina, Sasan Karimi, Cameron W Brennan and 3 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. A framework for fibrolamellar carcinoma research and clinical trials.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

William J HammondPediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York.
Gadi LalazarLaboratory of Cellular Biophysics, The Rockefeller University, New York City, New York.
James A SaltsmanPediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York.
Benjamin A FarberPediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York.
Enrico DanzerPediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York.
Tshering C SherpaLaboratory of Cellular Biophysics, The Rockefeller University, New York City, New York.
Charles D BandaLaboratory of Cellular Biophysics, The Rockefeller University, New York City, New York.
Jeffrey R AndolinaDepartment of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, New York.
Sasan KarimiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York.
Cameron W BrennanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York.
Michael S TorbensonDivision of Anatomic Pathology, Department of Pathology, Mayo Clinic, Rochester, Minnesota.
Michael P La QuagliaPediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York.
Sanford M SimonLaboratory of Cellular Biophysics, The Rockefeller University, New York City, New York.
Rockefeller University · USMemorial Sloan Kettering Cancer Center · USMayo Clinic · USUniversity of Rochester Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Cellular Pathogenesis of Fibrolamellar Hepatocellular CarcinomaR56CA207929 · NCI · ROCKEFELLER UNIVERSITY · PI SIMON, SANFORD M · 2016 to 2017
$593k
NCATS NIH HHS UL1 TR001866NCI NIH HHS P30 CA008748NCI NIH HHS R56 CA207929
6 · The paper itself

Abstract

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver malignancy in adolescents and young adults. Surgery is the mainstay of therapy for primary and metastatic disease. Most patients relapse, with development of both local and distant metastases. Brain metastases from solid tumors are rare in the pediatric and young adult population. Here, we document three patients with brain metastases from FLHCC, confirmed by histology and molecular characterization of the chimeric fusion DNAJB1-PRKACA, each necessitating neurosurgical intervention. These observations highlight the ability of FLHCC to metastasize to the brain and suggest the need for surveillance neuroimaging for patients with advanced-stage disease.

Indexed as

Brain NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsNeuroimagingNeurosurgical ProceduresAdolescentCyclic AMP-Dependent Protein Kinase Catalytic SubunitsFemaleHSP40 Heat-Shock ProteinsHumansNeoplasm MetastasisOncogene Proteins, FusionCyclic AMP-Dependent Protein Kinase Catalytic SubunitsDNAJB1 protein, humanHSP40 Heat-Shock ProteinsOncogene Proteins, FusionPRKACA protein, humanadolescent and young adult tumorsbrainfibrolamellarliverrare tumorstumor biologytumors

Identifiers

PMID29286561
PMCPMC6028006
OpenAlexW2780545155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.